Valuation: Larimar Therapeutics, Inc.

Market Cap 386M 338M 311M 287M 541M 37.19B 553M 3.72B 1.46B 18.22B 1.45B 1.42B 62.71B P/E 2026 *
-2.29x
P/E 2027 * -2.97x
Enterprise Value 210M 183M 169M 156M 294M 20.21B 300M 2.02B 795M 9.9B 788M 771M 34.07B EV / Sales 2026 *
-
EV / Sales 2027 * 3.12x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+0.82%
1 week-13.55%
Current month+21.31%
1 month+1.65%
3 months-22.92%
6 months+18.21%
Current year-2.89%
1 week 3.54
Extreme 3.535
3.84
1 month 2.92
Extreme 2.92
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer - 2018-04-30
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Buy

Director

50,000 0.0584%
5/19/26 Free

Director

55,150 0.0644%
5/19/26
Deerfield Management Co. LP
FreeCompany 55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%-13.55%+15.26%+15.99% 386M
-0.43%-1.53%+54.87%+56.22% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+3.24%+2.30%+36.36%-5.61% 19.36B
+0.04%-1.81%+34.32%-32.50% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+3.62%+0.50%+34.00%+646.86% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.36%-3.72%+40.05%+162.90% 23.39B
Weighted average by Cap. -1.43%-2.37%+41.30%+137.45%

Financials

2026 *2027 *
Net sales - 57.06M 49.87M 46.02M 42.42M 79.95M 5.5B 81.72M 550M 216M 2.69B 214M 210M 9.27B
Net income -157M -138M -127M -117M -221M -15.16B -225M -1.52B -597M -7.43B -591M -578M -25.56B -157M -137M -126M -116M -219M -15.08B -224M -1.51B -594M -7.39B -588M -575M -25.43B
Net Debt -176M -154M -142M -131M -247M -16.99B -253M -1.7B -669M -8.32B -662M -648M -28.64B -208M -182M -168M -155M -291M -20.02B -298M -2B -788M -9.81B -781M -764M -33.76B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-17 US$3.700 +0.82% 1,389,140
26-07-16 US$3.670 -3.67% 1,336,205
26-07-15 US$3.810 +2.42% 1,269,914
26-07-14 US$3.720 -0.13% 1,842,147
26-07-13 US$3.725 -12.97% 2,297,804
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.700USD
Average target price
14.40USD
Spread / Average Target
+289.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock